Summary
CStone Pharmaceuticals (2616) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has CStone Pharmaceuticals ever had a stock split?
CStone Pharmaceuticals Profile
| Biotechnology Industry | Healthcare Sector | Jianxin Yang CEO | HKEX Exchange | G2588M100 CUSIP |
| CN Country | 135 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
CStone Pharmaceuticals is a pioneering biopharmaceutical company engaged in the research, development, and commercialization of innovative immuno-oncology and precision medicines. With a focus on meeting the unmet medical needs of cancer patients both within China and globally, CStone Pharmaceuticals has established a significant presence in the oncology sector. Since its inception in 2015, the company has been dedicated to offering cutting-edge treatments aimed at improving patient outcomes. Headquartered in Suzhou, China, CStone Pharmaceuticals stands as a leading entity in the fight against cancer through its robust pipeline of therapeutic candidates and marketed drugs.
Products and Services
Sugemalimab: A pioneering monoclonal antibody that targets the programmed death (PD) ligand 1, providing a novel approach to immuno-oncology treatments.
GAVRETO: An innovative RET inhibitor designed for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, showcasing CStone's commitment to targeting genetic drivers of cancer.
Avapritinib: A KIT/PDGFRA inhibitor used for treating adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation, highlighting the company's focus on precision medicine.
Nofazinlimab: A PD-1 antibody under development for the treatment of patients with hepatocellular carcinoma, reflecting CStone's ongoing research into immuno-oncology solutions.
Ivosidenib: An isocitrate dehydrogenase 1 (IDH1) inhibitor aimed at treating adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation, further extending the company’s portfolio in precision oncology.
Other products in pipeline: CS1002, CS2006, CS3005, CS2007, CS2008, CS6001, and CS500 targeting solid tumors, and CS5001 designed for both solid tumors and hematologic malignancies, represent CStone's extensive research and development efforts towards providing a diverse array of cancer therapies.
